Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diffuse Large B Cell Lymphoma
Clinical trial register · United Kingdom · industry-sponsored

Diffuse Large B Cell Lymphoma Trials in the UK, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2879 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Oct 2026, 03:15 UTC
2879
Studies in scope
industry-sponsored, all four open statuses
1389
Recruiting now
open to new participants
547
Lead sponsors
across recruiting studies
Top sites
London 10 Birmingham 5 Sutton 5 Nottingham 5 Manchester 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Genmab4 Merck Sharp & Dohme LLC2 Incyte Corporation2 AbbVie2 Kartos Therapeutics, Inc.1
Site city
London10 Birmingham5 Sutton5 Nottingham5 Manchester5
All 33 cities
Target enrolment
to

Diffuse Large B Cell Lymphoma trials in the UK

15 of 2879 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
AbbVie
Observational
700
Milton Keynes, Truro, Cheltenham, Portsmouth, Airdrie, Nottingham, Manchester, Newcastle upon Tyne
2025-03-28
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Active, closed
Genmab
Phase 3
379
Truro, Airdrie, Nottingham, Newcastle upon Tyne
2024-08-13
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Leeds, London, Manchester
2023-04-04
Active, closed
Genmab
Phase 3
900
Birmingham, London, Norwich, Edinburgh
2023-02-08
Active, closed
Incyte Corporation
Phase 3
82
Antrim, Belfast
2022-12-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Aberdeen, Truro, London-Camden
2022-01-14
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Leeds, London, Southampton
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
270
Glasgow, Leeds, London, Manchester, Nottingham
2021-02-23
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
Genmab
Phase 1/2
543
Manchester, Newcastle upon Tyne, Plymouth
2020-11-03
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
240
Birmingham, London, Sandwich
2020-08-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Gloucester, Southampton, Sutton, Harrow, Leeds, Cambridge, Liverpool, London
2014-11
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 October 2026. https://priyalifescience.com/clinical-trials-uk/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,879 studies in total at the last sync on 23 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition Diffuse Large B Cell Lymphoma.

How many Diffuse Large B Cell Lymphoma trials are recruiting in the UK?

5 of the 15 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B Cell Lymphoma), 15 studies
PhaseStudiesRecruitingShare
Phase 37046.7%
Phase 1/24326.7%
Observational116.7%
Phase 1106.7%
Phase 2106.7%
Phase 2/3116.7%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B Cell Lymphoma)
Lead sponsorStudiesRecruiting
Genmab40
AbbVie21
Incyte Corporation20
Merck Sharp & Dohme LLC22
Hoffmann-La Roche10
Kartos Therapeutics, Inc.11
Karyopharm Therapeutics Inc10
Novartis Pharmaceuticals11
Seagen, a wholly owned subsidiary of Pfizer10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.